Enjoying the archive? Get new posts in your inbox.
Coverage
+4
Aug 8, 2026
•
13 min read
Every First Claim Is Denied. That's the Design.
One month into the Medicare GLP-1 Bridge, the denial at the counter isn't a coverage decision — and CMS built no appeals process for the ones that are.
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
Lipids
+1
Jul 18, 2026
•
2 min read
The PCSK9 Pill Is Here. The Needle Was the Barrier.
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
